Keytruda/Padcev Combo Slashes Bladder Cancer Progression Risk by 47% in Phase 3 Trial
Summary
Merck's Keytruda, in combination with Pfizer and Astellas Pharma's Padcev (enfortumab vedotin), reported highly positive Phase 3 trial results for muscle-invasive bladder cancer. The combination demonstrated a 47% reduction in the risk of tumor recurrence, progression, or death, and a 35% reduced risk of death compared to standard chemotherapy. This significant data suggests a potential new standard of care, expanding the market for both drugs. This news is particularly impactful for Merck, as it helps to diversify Keytruda's revenue streams following the company's recent 10-K warning about future Keytruda revenue declines due to patent expiration and IRA pricing. For Pfizer, it reinforces the value of Padcev. Traders will now watch for regulatory submissions and approvals.
At the time of this announcement, MRK was trading at $121.49 on NYSE in the Life Sciences sector, with a market capitalization of approximately $300.4B. The 52-week trading range was $73.31 to $125.14. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.